Pharmaceuticals Veteran George R. Stevenson Joins the GeneriCo Board of Directors

Print
| Source: GeneriCo, LLC

ST. LOUIS, Jan. 27, 2017 (GLOBE NEWSWIRE) -- GeneriCo, LLC (“GeneriCo”), a global generic specialty pharmaceutical company, is pleased to announce that George R. Stevenson has joined the Company’s Board of Directors as the new Chairman of the Board.  Mr. Stevenson brings deep generic and brand pharmaceutical expertise to the GeneriCo Board and is a seasoned pharmaceutical executive with many years of leadership in this dynamic marketplace.  Mr. Stevenson most recently served as the President and Chief Executive Officer of Kremers Urban Pharmaceuticals (Division of UCB, Inc.) which was acquired in 2015 by Lannett Company, Inc. for $1.23B.

At Kremers Urban, George Stevenson led the Company’s growth from minimal value in 2007 to $1.23 billion in 2015.  As part of this growth, Mr. Stevenson oversaw the approval of 12 FDA approved products, with another 30 products added to the R&D portfolio. Prior to Kremers Urban, Mr. Stevenson was Vice President of Generic Business & Trade Affairs at Endo Pharmaceuticals, and prior to that was successful during his professional career at Sandoz Inc. (Division of Novartis AG), Apothecon (Division of BMS), United Research Laboratories and Sun Company.

Tom Brya, CEO GeneriCo, stated, “We are thrilled to add George Stevenson to our Board of Directors.  He will bring a depth of generic pharmaceutical expertise and leadership to add to our Board.  His guidance will be invaluable as our ANDA pipeline products progress to approval and launch.” 

About GeneriCo

GeneriCo is a generic pharmaceutical company focused on developing and marketing niche, high barrier drugs in the U.S. utilizing its proprietary data-driven, algorithm-based product selection process. The Company employs a four-pillar collaboration business strategy capitalizing on management’s deep industry knowledge and experience to collaborate with partners on the discovery, formulation, development and manufacture of generic drugs. The Company expects its 1st  internally-developed ANDA to be filed in 2017, with a total of 2 ANDAs filed by the end of 2017.

GeneriCo is led by a management team with 195 years of combined experience in formulation, manufacturing and commercial leadership. The team has successfully filed and launched over 200 generic drugs and created more than $30B of firm value.

For more information, please visit www.genericopharma.com 

GeneriCo Investor Contact: 
Deborah Knobelman, PhD – Chief Financial Officer 
Phone Number: +1.646.221.5830 
Email: deb.knobelman@genericopharma.com